Each public meeting of CEPAC will involve deliberation and voting on key questions related to the supplementary analysis of the AHRQ review being presented by ICER. Members of CEPAC will discuss issues regarding the application of the available evidence to guide clinical decision-making and payer policies. The key questions are developed by ICER with significant input from members of the CEPAC Advisory Board to ensure that the questions are framed to address the issues that are most important in applying the evidence to practice and medical policy decisions.
effectiveness, there are two interrelated questions: the relative magnitude of differences in risks and benefits; and the relative confidence that the body of evidence can provide in the accuracy of estimates of risks and benefits. Considering these two issues together is required in order to make a judgment of whether the evidence is "adequate" to demonstrate that one intervention is equivalent to or superior than another. 2. Issues related to individual patient preferences and values, provider training, volume, or other factors that should be considered in judging the evidence on clinical effectiveness and value. 3. Weighing the evidence on cost-effectiveness and projected budgetary impact to determine the comparative value of various management options for key patient populations. 4. Comments or recommendations related to broader considerations of public health, equity, disparities, and access.
Comparative Value
When a majority of CEPAC votes that the evidence is adequate to demonstrate that an intervention produces patient outcomes as good as or better than a comparator, the Council will also be asked to vote on whether the intervention represents a "high," "reasonable," or "low" value. The value "perspective" that CEPAC will be asked to assume is that of a state Medicaid program that must make resource decisions within a fixed budget for care. While information about hypothetical budget tradeoffs will be provided, CEPAC will not be given prescribed boundaries or thresholds for budget impact or incremental cost-effectiveness ratios to guide its judgment of high, reasonable, or low value.
For each vote, Council members will be asked to identify which element of the information provided to them on "value" was most influential in their judgment, including: 1) information on the incremental cost for an additional benefit (or for reduction in risk); or 2) information on the budget impact of different care/payment scenarios. Council members will also be asked to describe briefly the rationale for their rating of comparative value.
Additional comments/recommendations CEPAC will be invited to comment or make recommendations on the following after each vote for comparative clinical effectiveness and value:
Are there any factors related to the following that should also be considered? 
Comparative Clinical Effectiveness and Value: Diagnosis of OSA in Adults
Comparative Clinical Effectiveness
Note: Type II monitors are excluded from consideration in these voting questions due to the lack of studies assessing Type II monitors, though this in no way implies that Type II monitors are ineffective in diagnosing OSA.
Voting Stipulations
Based on the findings of the AHRQ review, and time limitation of the CEPAC meeting, we will ask CEPAC for unanimous consent to the following stipulations. If there is dissent, then a formal vote will be taken.
 There is insufficient evidence to distinguish the diagnostic accuracy of Type III vs. Type IV home monitors, and available evidence suggests their sensitivity and specificity largely overlaps.
Voting Questions:
1. Is the evidence adequate to demonstrate that Type III-IV home monitors are equivalent to polysomnography in diagnosing OSA?
2. Is the evidence adequate to demonstrate that a phased diagnostic approach using the Berlin questionnaire to identify candidates for polysomnography is equivalent to using polysomnography alone in all patients in whom there is a clinical suspicion for the diagnosis of OSA?
3. Is the evidence adequate to demonstrate that a phased diagnostic approach using externallyvalidated clinical predication rules to identify candidates for polysomnography is equivalent to using polysomnography alone in all patients in whom there is a clinical suspicion for the diagnosis of OSA?
Comparative Value 1. Based on reimbursement levels provided in this report, would you judge the comparative value of a phased diagnostic approach using the Berlin questionnaire compared to polysomnography alone to be: 1) high value; 2) reasonable value; or 3) low value?
2. Based on reimbursement levels provided in this report, would you judge the comparative value of a phased diagnostic approach using externally-validated clinical prediction rules compared to polysomnography alone to be: 1) high value; 2) reasonable value; or 3) low value?
3. Based on reimbursement levels provided in this report, would you judge the comparative value of a home-based care pathway (Type III-IV home monitor with auto-CPAP) compared to an in-lab care pathway (split-night polysomnography and CPAP) to be: 1) high value; 2) reasonable value; or 3) low value?
Broader Considerations of Public Health, Equity, and Access
Are there any considerations related to public health, equity, disparities in access or outcomes for specific patient populations, or other social values that should also be considered in medical policies related to the use of portable home monitors, PSG, or phased diagnostic approaches in patients in which there is a clinical suspicion of the diagnosis of OSA?
Comparative Clinical Effectiveness and Value: Treatment of OSA in Adults

Comparative Clinical Effectiveness
 There is insufficient evidence to demonstrate that other interventions (e.g., medication, palatal implants, bariatric surgery, acupuncture, nasal dilator strips, etc.) are better than continuous positive airway pressure (CPAP) in treating adults with OSA.
 There is insufficient evidence to demonstrate that any one form of mandibular advancement device (MAD) is more effective than any other in treating adults with OSA.
 There is insufficient evidence to demonstrate that any of the available intervention programs improve compliance with CPAP relative to usual CPAP care in adults with OSA. 2. Based on reimbursement levels provided in this report, would you judge the comparative value of MAD compared to CPAP for mild-to-moderate OSA (AHI 5-30 events/hour) to be: 1) high value; 2) reasonable value; or 3) low value?
Are there any considerations related to public health, equity, disparities in access or outcomes for specific patient populations, or other social values that should also be considered in medical policies related to the use of surgery, MADs, or CPAP in patients in whom there is a clinical suspicion of the diagnosis of OSA?
Other Comments or Recommendations
Are there specific actions that patients, providers, or insurers could take to improve the quality and value of care for patients with suspected or confirmed OSA?
What research is needed to fill the most important evidence gaps on the diagnosis and treatment of OSA?
